BRISTOL-MYERS SQUIBB CO CEDEAR EACH 3 REP 1

Bristol-Myers Squibb's shares rose 10.5% after a new schizophrenia treatment was approved, while AbbVie saw a 13% drop in shares due to its schizophrenia drug failing in clinical trials.

Bristol-Myers Squibb's price targets are updated by various firms: Redburn Atlantic at $53, Morgan Stanley at $39, BMO Capital at $61, and Goldman Sachs at $65, with an average rating of 'hold'.